Lancet Neurology
Papers 4539
1 page of 454 pages (4,539 results)
#1Yakeel T. Quiroz (UdeA: University of Antioquia)H-Index: 15
#2Henrik Zetterberg (University of Gothenburg)H-Index: 90
Last. Marina Villada (UdeA: University of Antioquia)
view all 25 authors...
Summary Background Neurofilament light chain (NfL) is a promising biomarker of active axonal injury and neuronal degeneration. We aimed to characterise cross-sectional and longitudinal plasma NfL measurements and determine the age at which NfL concentrations begin to differentiate between carriers of the presenilin 1 (PSEN1) E280A (Glu280Ala) mutation and age-matched non-carriers from the Colombian autosomal dominant Alzheimer's disease kindred. Methods In this cross-sectional and longitudinal c...
1 CitationsSource
#1Lisa B. GrechH-Index: 3
#2Robert Hester (University of Melbourne)H-Index: 36
Last. Ernest G. Butler (Monash University, Clayton campus)H-Index: 4
view all 5 authors...
#1Günther Deuschl (CAU: University of Kiel)H-Index: 85
#2Paul Krack (University of Bern)H-Index: 1
#1Elena MoroH-Index: 20
#1Elena MoroH-Index: 40
Last. Claudio L. Bassetti (University of Bern)H-Index: 76
view all 9 authors...
2 CitationsSource
#1Michael BraininH-Index: 43
#2Valery L. FeiginH-Index: 73
Last. Vladimir HachinskiH-Index: 80
view all 6 authors...
1 CitationsSource
#1Gustavo C. Román (Cornell University)H-Index: 35
#2J. Reis (UDS: University of Strasbourg)H-Index: 2
Last. Marco T. MedinaH-Index: 29
view all 12 authors...
1 CitationsSource
#1Maria Pia Sormani (UniGe: University of Genoa)H-Index: 65
16 CitationsSource
#1S Winkler (TUM: Technische Universität München)H-Index: 28
#2Samuel Knauss (Humboldt University of Berlin)H-Index: 1
Last. Parthasarthy Satishchandra (National Institute of Mental Health and Neurosciences)H-Index: 23
view all 24 authors...
1 CitationsSource
#1Rachael I. Scahill (UCL: University College London)H-Index: 42
#2Paul Zeun (UCL: University College London)H-Index: 1
Last. Christelle Langley (University of Cambridge)H-Index: 1
view all 28 authors...
Summary Background Disease-modifying treatments are in development for Huntington's disease; crucial to their success is to identify a timepoint in a patient's life when there is a measurable biomarker of early neurodegeneration while clinical function is still intact. We aimed to identify this timepoint in a novel cohort of young adult premanifest Huntington's disease gene carriers (preHD) far from predicted clinical symptom onset. Methods We did the Huntington's disease Young Adult Study (HD-Y...
1 CitationsSource
Top fields of study
Physical therapy